Genentech’s Tecentriq wins US nod for lung cancer

06:14 EDT 19 Oct 2016 | PharmaTimes

Roche-group Genentech's anti-PDL1 cancer immunotherapy Tecentriq has been approved in the US to treat certain forms of lung cancer, expanding its scope from the original bladder cancer indication.

Original Article: Genentech’s Tecentriq wins US nod for lung cancer


More From BioPortfolio on "Genentech’s Tecentriq wins US nod for lung cancer"

Quick Search

Relevant Topics

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...

Allergies Automimmune Disease Human Papillomavirus (HPV) Immunology Vaccine Immunology is the study of immunity and the defence mechanisms of the body. A greater understanding of immunology is needed to develop vaccines, understand ...